Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Keros Therapeutics Price Performance
KROS stock opened at $12.74 on Tuesday. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The business has a 50 day simple moving average of $10.94 and a two-hundred day simple moving average of $30.31. The company has a market capitalization of $516.76 million, a price-to-earnings ratio of -2.45 and a beta of 1.39.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Braidwell LP boosted its stake in Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after buying an additional 1,187,199 shares during the last quarter. Lynx1 Capital Management LP bought a new stake in Keros Therapeutics in the 4th quarter worth approximately $8,612,000. Millennium Management LLC raised its holdings in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after acquiring an additional 305,169 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Keros Therapeutics during the 4th quarter valued at approximately $3,958,000. Finally, Integral Health Asset Management LLC grew its holdings in shares of Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company's stock valued at $7,124,000 after purchasing an additional 250,000 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.
Analyst Ratings Changes
KROS has been the subject of several research reports. Wedbush reaffirmed a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Keros Therapeutics in a report on Tuesday, April 1st. Scotiabank dropped their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Truist Financial decreased their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Finally, Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $40.33.
Get Our Latest Research Report on Keros Therapeutics
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
